NFKB1 and ovarian carcinoma: Huang et al. (2020) stated the anticancer activity of EGCG against endometrial, breast, and ovarian cancers via Nrf2 activation, NF‐κB downregulation, and interaction with DNMTs and histone deacetylases (HDACs).